Pipeline tracker sets a fourth-quarter 2026 window for the Foundayo type 2 diabetes decision

Eli Lilly's oral GLP-1 drug Foundayo (orforglipron) could receive an FDA decision on a type 2 diabetes indication in the fourth quarter of 2026, according to Prime Therapeutics' August 2026 GLP-1 pipeline update ^[1]. The update notes that Lilly submitted the application during the second quarter of 2026 under the FDA's Commissioner's National Priority Voucher pilot program, a pathway that can shorten review times ^[1].

The same tracker had placed a separate decision, a cardiovascular indication for Mounjaro (tirzepatide), in the third quarter of 2026. The FDA granted that approval on August 27, matching the tracker's timing estimate ^[1].

It is important to understand what these timelines are and are not. Prime Therapeutics' report is built from voucher-based estimates, not from published Prescription Drug User Fee Act (PDUFA) dates that the FDA typically assigns to standard applications ^[1]. That means the fourth-quarter 2026 window for Foundayo's diabetes decision is a projection drawn from when the voucher review clock is expected to run out, not a date the FDA itself has publicly confirmed ^[1].

Separately, reporting on Lilly's broader pipeline strategy describes the company's incretin franchise, which includes tirzepatide and orforglipron, as central to funding its other drug development efforts in 2026 ^[2]. That reporting does not provide additional specifics on the orforglipron diabetes review timeline beyond what the Prime Therapeutics tracker states ^[2].

Why it matters for patients

For people with type 2 diabetes who take pills rather than injections, or who are interested in an oral GLP-1 option, the timing of this decision affects when Foundayo might become available as a diabetes treatment in the United States. Foundayo is orforglipron, a molecule distinct from the injectable semaglutide products (Ozempic, Wegovy, Rybelsus) and injectable tirzepatide products (Mounjaro, Zepbound) ^[1].

Because the fourth-quarter 2026 estimate comes from a voucher-based projection rather than a confirmed FDA date, patients and clinicians should treat it as an approximate window rather than a fixed deadline. The tracker itself flags this distinction, noting that voucher timelines are estimates and not the same as published PDUFA dates ^[1]. The Mounjaro cardiovascular approval landing in the same quarter the tracker predicted offers one data point suggesting these voucher-based estimates can align with actual FDA action, but that is a single example and does not guarantee the same outcome for Foundayo ^[1].

It is not yet known from these sources what specific dosing, label language, or safety data the FDA will require for a type 2 diabetes indication of orforglipron, nor is it known whether the fourth-quarter 2026 window will hold if the review encounters delays or requests for additional information. Patients currently managing diabetes with other GLP-1 or non-GLP-1 medications do not need to change their current treatment plans based on a pending regulatory decision for a different product.

What happens next

The fourth-quarter 2026 window covers the period from October through December 2026, based on the Prime Therapeutics estimate for the orforglipron type 2 diabetes submission ^[1]. No specific decision date within that quarter has been published. The Mounjaro cardiovascular indication, which the same August update placed in the third quarter of 2026, was approved by the FDA on August 27, 2026 ^[1]. Readers following the orforglipron diabetes decision should watch for either a formal FDA action or an updated estimate in a future Prime Therapeutics pipeline report, as the current figure remains a projection rather than a confirmed regulatory date ^[1].